



Appointment of Bruce Hewett as a non-executive director.

BTC health (ASX:BTC) today announced the appointment of Bruce Hewett as a non-executive director.

Bruce graduated as a pharmacist and has had over 30 years experience in all aspects of the pharmaceutical industry. He has held a number of senior leadership roles, initially with Janssen-Cilag and Faulding DBL and more recently with the UK based speciality pharmaceutical and services company, Clinigen plc. Bruce brings a strong track record of founding and building businesses in the Australian and New Zealand pharmaceutical industries and much of this success has been underpinned by his extensive network of industry contacts around the world.

BTC health Chairman Richard Treagus commented: "We are delighted that Bruce is joining the Board at this point in our growth strategy. We share a strong vision to build our speciality health businesses in Australia and New Zealand and to have the benefit of Bruce's industry experience and commercial insights is indeed a very exciting and positive development."

Forward-looking Statements

This ASX-announcement may contain forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.

About BTC health

BTC health is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in businesses that acquire, develop and commercialize innovative products in the healthcare sector, and which can benefit from greater access to growth capital. The company has the long-term objective of building a group of complementary high-growth businesses which when operating together generate better patient health outcomes and value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary